$5.000
+0.010 (+0.20%)At close
- High
- 5.010
- Open
- 5.000
- VWAP
- 5.00
- Vol
- 1.16M
- Mkt Cap
- 193.28M
- Low
- 4.990
- Amount
- 5.79M
- EV/EBITDA, TTM
- -7.45
2seventy bio, Inc. is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The Company is focused on the commercialization and development of Abecma (idecabtagene vicleucel). Abecma is its B cell maturation antigen (BCMA)-targeted CAR T cell therapy for multiple myeloma, in collaboration with their partner Bristol Myers Squibb (BMS). ABECMA is a BCMA-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. Abecma uses a lentiviral vector (LVV), to deliver a chimeric antigen receptor (CAR), with the potential to program a patient’s own T cells to recognize the plasma cell specific BCMA, protein on the cell surface.
Valuation Metrics
Events Timeline
News
7.004-16PRnewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BHLB, TSVT, RDFN on Behalf of Shareholders
9.004-01NASDAQ.COMCHMP Issues Positive Opinion for Label Expansion of BMY's Opdivo
3.003-23NASDAQ.COM$TSVT Earnings Preview: Recent $TSVT Insider Trading, Hedge Fund Activity, and More
7.003-17PRnewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RDUS, NDOI, TSVT, RDFN on Behalf of Shareholders
8.503-14Businesswire2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVT
TSVT FAQ — answered by Alphio AI
2seventy bio, Inc. is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The Company is focused on the commercialization and development of Abecma (idecabtagene vicleucel). Abecma is its B cell maturation antigen (BCMA)-targeted CAR T cell therapy for multiple myeloma, in collaboration with their partner Bristol Myers Squibb (BMS). ABECMA is a BCMA-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. Abecma uses a lentiviral vector (LVV), to deliver a chimeric antigen receptor (CAR), with the potential to program a patient’s own T cells to recognize the plasma cell specific BCMA, protein on the cell surface. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.